IUGR Clinical Trial - Viagra for the Treatment of IUGR

Status Not yet recruiting

Clinical Trial Summary

It has been suggested that Viagra (or other drugs that inhibit PDE-5, the enzyme that normally inhibits blood vessels’ ability to expand) may have beneficial effects in hypertensive pregnancy and, possibly, preeclampsia.The benefits of Viagra were observed without any reduction in maternal blood pressure, thereby dissociating hypertension per se from the loss of NO (nitrous oxide) signaling in the uterine circulation.Following publications, suggesting that sildenafil citrate used as a therapeutic agent may improve myometrial perfusion in IUGR gestations by promoting myometrial small artery vasodilatation, decreasing peripheral resistance and increasing flow within the uteroplacental bed, we intend to administer this medication to parturients where intauterine growth restriction and pregnancy associated hypertension have been diagnosed in an attempt to induce vasodilatation and improved uteroplacental perfusion resulting in improved fetal growth.

Clinical Trial Description

Each participant will receive, after informed consent a 25 mg tablet of Viagra [sildenafil citrate ]orally. The uteroplacental perfusion will be measured using transvaginal and transabdominal ultrasound Doppler velocimetry studies, before and after 2, 4, and 24 hours of Viagra ingestion. If no significant side effects are recorded, the protocol will be repeated , 48 hours after the first tablet ingestion, but using 50 mg Viagra.In cases of positive and encouraging results and if no serious side effects are detected we shall consider repeated administration of the lowest effcetive dose of viagra in an attempt to prevent prematurity and possibly reach term.our study will evaluate the effects of Viagra on uterine blood flow changes during pregnancy, and possible changes in other systems that contribute to normal fetal growth and development, in parallel to monitoring general and possible deleterious effects on the retina or other possible maternal or fetal organs. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

IUGR

Clinical Trial Details

NCT number	NCT00347867
Study type	Interventional
Source	Rambam Health Care Campus
Contact	Zeev Blumenfeld, MD
Phone	972-4-8542577
Email	z_blumenfeld@rambam.health.gov.il
Status	Not yet recruiting
Phase	Phase 4
Start date	July 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04506970` - Predicting Placental Pathologies by Ultrasound Imaging
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT02813525` - Ultrasound Monitoring of Fetuses With Vascular Intra-uterine Growth Restriction (IUGR) Using the Isthmus Systolic Index (ISI): Feasibility, Comparison to Normal Fetuses and Association With Perinatal Mortality	N/A
Not yet recruiting	`NCT02541110` - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler	N/A
Recruiting	`NCT05551078` - Thrombophilia Screening After Severe IUGR
Completed	`NCT01669525` - Placental Growth and Adverse Pregnancy Outcomes	N/A
Completed	`NCT03515759` - Fetal Doppler Indices in Predicting Perinatal Outcome Among Severely Hypertensive Pregnant Patients.
Active, not recruiting	`NCT02738463` - Maternal Serum Ferritin and Low Neonatal Birth Weight	N/A
Terminated	`NCT00634855` - Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR
Not yet recruiting	`NCT03443297` - Early Versus Delayed Feeding in Preterm Growth-Restricted Infants	N/A
Recruiting	`NCT05410080` - the Efficacy of Fetal Arterial and Venous Doppler Indices in Predicting Perinatal Outcome
Completed	`NCT03954418` - Transport of Artificial Sweeteners During Pregnancy	N/A
Not yet recruiting	`NCT04729361` - CGH-array in Prenatal Diagnosis of Isolated Severe and Early Intra-uterine Growth Restriction
Recruiting	`NCT02391519` - Effects of High Altitude on AMPK Activation
Active, not recruiting	`NCT02583763` - Cardiac Displacement From Third Trimester to Early Childhood
Terminated	`NCT02397291` - Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies.	N/A
Completed	`NCT04508751` - PED NEONAT 20-000599 Fetal Body Composition	Phase 1
Recruiting	`NCT02382601` - Longitudinal Study of Intra-Uterine Growth Restriction
Recruiting	`NCT06268509` - Nutrition Optimalization Among Pregnant Women to Improve Maternal and Neonatal Outcome in DKI Jakarta	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.